Screener
Perspective Therapeutics CATX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Perspective Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:34 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-342512
FAQ
- What is Perspective Therapeutics's cash & equivalents?
- Perspective Therapeutics (CATX) reported cash & equivalents of $48.49M in Q2 2026.
- How has Perspective Therapeutics's cash & equivalents changed year-over-year?
- Perspective Therapeutics's cash & equivalents increased by 68.1% year-over-year, from $28.85M to $48.49M.
- What is the long-term trend for Perspective Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Perspective Therapeutics's cash & equivalents has grown at a 26.2% compound annual growth rate (CAGR), from $9.59M to $30.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Perspective Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude